SavedAdd your journal

Journals / Tıp Araştırmaları Dergisi / 2005 / Cilt: 3 - Sayı: 2

Insulin-like growth factor system and cancer

İnsülin benzeri büyüme faktörü sistemi ve kanser

MUSTAFA KELEŞ
Mehmet TÜRKELİ
Pages
39–43
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum IGF-I levels were found to be increased and IGFBP-3 to be decresed in some tumor types.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Insulin-like growth factor-I (IGF-I) is a peptide hormone having mitogenic and antiapoptotic effects.
📊
Key Findings & Data:But, insulin-like growth factor binding protein-3 (IGFBP-3) is a protein having an antiproliferative property and inhibits the mitogenic activity of IGF-I by stimulating apoptosis.
💡
Conclusion & Impact:Serum IGF-I levels were found to be increased and IGFBP-3 to be decresed in some tumor types.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Neoplazmlar · İnsülin-benzeri büyüme faktörü I · Somatomedinler

Abstract

Insulin-like growth factor-I (IGF-I) is a peptide hormone having mitogenic and antiapoptotic effects. But, insulin-like growth factor binding protein-3 (IGFBP-3) is a protein having an antiproliferative property and inhibits the mitogenic activity of IGF-I by stimulating apoptosis. In some epidemiological studies, it has been reported that a link was observed betwen serum concentration of IGF-I and IGFBP-3 with increased risks of breast, prostate, colorectal and lung cancer. Serum IGF-I levels were found to be increased and IGFBP-3 to be decresed in some tumor types.

Özet

İnsülin benzeri büyüme faktörü-I (IGF-1), mitojenik ve antiapopitotik etkiye sahip olan peptid yapıda bir hormondur. İnsülin benzeri büyüme faktörü bağlayıcı protein-3 (IGFBP-3) ise apopitozisi uyararak IGF-l'in mitojenik etkisini inhibe eden ve antiproliferatif etkiye sahip bir proteindir. Birçok epidemiyolojik çalışmada serum IGF-I ve IGFBP-3 seviyelerinin göğüs, prostat, kolon ve akciğer gibi pek çok kanser için artmış risk ile ilişkili olduğu rapor edilmiştir. Birçok tümör tipinde serum IGF-I düzeylerinin yükseldiği ve IGFBP-3 düzeylerinin de düştüğü saptanmıştır.

🔖

Cite This Article

KELEŞ, M., TÜRKELİ, M. (2005). Insulin-like growth factor system and cancer. Tıp Araştırmaları Dergisi, Cilt: 3 - Sayı: 2, 39–43. https://ajindex.com/articles/361674

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Daughaday WH, Rotwein P. Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev 1989; 10:68-91
  2. Kato H, Faria TN, Stannart B, et al. Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. "J Biol Chem 1993; 265:2655-2661
  3. Frattali AL, Peşsin JE. Relationship between alpha subunit legant occupancy and beta subunit autophosphorylation in insülin/insulin-like growth factor-I hybrid receptors. J Biol Chem 1993; 268: 7393-7400
  4. MacDonald RG, Pfeffer SR, Coussens L, et al. A singal receptor binds both insulin-like growth factor-II and mannose 6-phosphate. Science 1988; 239: 1134-1137
  5. Lobel P, Dahms NM, Kornfeld S. Clonning and sequence analysis of the cation- independent mannose 6-phosphate receptor. J Biol Chem 1988; 263: 2563 2570
  6. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34
  7. Lamson G, Giudice L, Rosenfelt RG. The insulin-like growth factor binding proteins structural and molecular relationships. Growth Factors 1991; 5: 19-28
  8. Buckbinter L, Talbott R, Velasco-Miquel S, et al. Induction of the growth inhibitor IGFBP-3 by p53. Nature 1995; 377: 646-649
  9. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143- 163
  10. Giovannucci E. Insulin-like growth factor-I and their binding protein-3 and risk of cancer. Horm Res 1999; 51(suppl 3); 34-41
  11. Manni A, Badger B. Wei L, Zaenglein A, Grove R, Khin S, Heitjan D, Shimasaki S, Ling N. Hormonal regulation of insulin-like growth factor II and insulin-like growth factor binding protein expression by breast cancer cells in vivo: evidence for stromal epithelial interactions. Cancer Res 1994; 54: 2934-2942
  12. Jerome L, Shiry L, Jones BL. Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 2003;10: 561-578
  13. Fürstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002; 3: 298-302
  14. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-1489
  15. Nolan CM, Kyle JW, Watanabe H, Sly WS. Binding of insulin-like growth factor II (IGF-II) by human cation-independent mannose 6-phosphate receptor/IGF II r